Evaluation of a new extraction platform in combination with molecular assays useful for monitoring immunosuppressed patients

Immune suppressive therapy after transplantation makes transplant recipients susceptible to a broad range of viral pathogens [1 –6]. Multiple factors can lead to viral reactivation after transplantation, including immune suppressive therapy, graft rejection, inflammation and tissue injury [1,7–11]. The first line therapeutic decision is whether and how to reduce the intensity of immune suppression, because the risk of th is therapy is graft rejection [1,12]. Several viruses including adenoviruses, cytomegalovirus (CMV), Epstein-Barr virus (EBV), enteroviruses, herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2), human herpesvirus 6 (HHV-6), influenza viruses A/B, parvovirus B19, polyomaviruses B K (BKPyV), and varicella zoster virus (VZV) have been recognized as significant pathogens in immunosuppressed patients including bone marrow and solid organ transplant recipients [13,14].
Source: Journal of Clinical Virology - Category: Virology Authors: Source Type: research